Pliant Therapeutics (PLRX) Financials

Pliant Therapeutics’ (NASDAQ:PLRX) financial statements show improving cost control and a lower cash burn, but the company remains a development-stage biotechnology business with no reported revenue and continuing losses. The latest figures cover the quarter ended June 30, 2026, with comparisons to quarterly statements from 2023 through 2025.

• Operating cash burn improved materially. Net cash used in operating activities declined to $12.8 million in Q2 2026 from $19.2 million in Q1 2026 and $40.6 million in Q2 2025. This is also substantially below the $45.3 million used in Q2 2024.
• Operating expenses were sharply lower. Total operating expenses fell to $23.9 million in Q2 2026 from $45.6 million in Q2 2025. Research and development spending declined to $16.7 million from $32.2 million, while selling, general and administrative expense decreased to $7.1 million from $13.4 million.
• The quarterly net loss narrowed. PLRX reported a net loss of $22.4 million, or $0.36 per share, in Q2 2026, compared with a restated net loss of $43.3 million, or $0.71 per share, in Q2 2025. The loss was also modestly higher than the $20.0 million loss in Q1 2026 but below the losses reported during much of 2024 and 2025.
• Debt exposure has been reduced. Long-term debt was zero at June 30, 2026, compared with approximately $30 million in each of the 2024 and 2025 comparison periods. Lower debt could reduce financial risk and interest obligations.
• Short-term liquidity remains substantial relative to current obligations. Cash and short-term investments totaled approximately $158.0 million at the end of Q2 2026, compared with $16.5 million of current liabilities. This represents a current ratio of roughly 9.9 times, although most of the liquidity is held in short-term investments rather than cash.
• Investment activity supported quarterly cash flow. Investing activities generated $15.5 million in Q2 2026 as $32.8 million of investments matured or were sold, partially offset by $17.3 million of investment purchases. This helped produce a $2.7 million increase in cash, but investment proceeds are not an operating source of revenue and may not recur.
• PLRX continues to report no revenue. Total revenue was zero in each of the reported quarters. The company’s financial performance therefore remains dependent on research progress, potential partnerships, financing, or eventual commercialization rather than product sales.
• The company remains unprofitable. Operating income was negative $23.9 million in Q2 2026, and accumulated retained earnings were negative $901.8 million. There is no evidence in the supplied statements that PLRX is close to reaching operating profitability.
• The liquidity base has contracted over the longer period. Cash and short-term investments declined from approximately $436.6 million at September 30, 2024, and $262.1 million at June 30, 2025, to $158.0 million at June 30, 2026. Total assets fell to $189.9 million from $299.8 million a year earlier and $445.7 million in Q3 2024.
• Continued cash burn could require future capital. Although Q2 2026 operating cash use improved, PLRX still consumed $12.8 million from operations during the quarter. If losses continue, the company may eventually need additional equity, debt, partnerships, or other financing, creating potential dilution or increased financial risk.

Overall, the statements point to a smaller and more disciplined cost structure, lower debt, and a slower near-term cash burn. However, the absence of revenue, ongoing clinical-development losses, shrinking liquid assets, and the possibility of future financing remain significant risks for investors.